公开(公告)号：EP3992292A1

公开(公告)日：2022-05-04

申请号：EP21760156.6

申请日：2021-02-26

申请人： RZNOMICS INC.

发明人： LEE, Seong-Wook ,  HAN, Seung Ryul

IPC分类号： C12N15/113 ,  A61K48/00 ,  A61K31/7105 ,  A61P25/28

摘要： The present invention relates to a trans-splicing ribozyme specific to Alzheimer's disease, and a use thereof. The trans-splicing ribozyme replaces RNA of genes that cause or increase the risk of Alzheimer's disease with RNA of genes that are beneficial for the treatment of the disease, thereby reducing the expression of the disease-causing genes and increasing the expression of the genes beneficial for the treatment of the disease, and thus can be usefully used to prevent or treat Alzheimer's disease.

公开(公告)号：EP4286518A1

公开(公告)日：2023-12-06

申请号：EP22742867.9

申请日：2022-01-21

申请人： RZNOMICS INC.

发明人： LEE, Seong-Wook ,  CHO, Eun Yi ,  KIM, Tae Young ,  PARK, Hye Rim

IPC分类号： C12N15/113 ,  C07K16/28 ,  A61K31/7088 ,  A61P35/00

摘要： The present disclosure relates to a cancer-specific trans-splicing ribozyme and a use thereof. The trans-splicing ribozyme does not act on normal tissues but is specifically expressed in cancer tissues, and thus the safety thereof is high and the expression efficiency thereof is excellent at the post-transcription level, and one or more target genes are connected to the 3' exon of the ribozyme so that a cancer therapeutic gene and an immune checkpoint inhibitor are expressed together when applied in vivo, and thus the present disclosure can be effectively used in cancer treatment.

公开(公告)号：EP3202909B1

公开(公告)日：2019-06-26

申请号：EP15847264.7

申请日：2015-07-23

申请人： RZNOMICS INC.

发明人： LEE, Seong Wook ,  KIM, Ju Hyun ,  JEONG, Jin Sook ,  HAN, Sang Young

IPC分类号： C12N15/85 ,  C12N9/22 ,  A61K31/713 ,  A61K38/43 ,  A61P35/00

公开(公告)号：EP4382135A1

公开(公告)日：2024-06-12

申请号：EP22853581.1

申请日：2022-08-08

申请人： RZNOMICS INC.

发明人： LEE, Seong-Wook ,  HAN, Seung Ryul ,  PARK, Hee Chul ,  CHOI, Changhoon ,  SHIN, Sungwon

IPC分类号： A61K48/00 ,  A61K31/7105 ,  A61P35/00 ,  C12N15/113

CPC分类号： C12N15/113 ,  A61K48/00 ,  A61K31/7105 ,  A61P35/00

摘要： The present invention relates to a cancer-specific trans-splicing ribozyme as a gene therapy product combined with radiotherapy. The ribozyme of the present disclosure is safe because of the cancer tissue-specific expression thereof and exhibits high expression efficiency at a post-transcriptional level and thus can be provided as a safe and effective gene therapy product. When administered after radiotherapy, the ribozyme exhibits high anticancer effects even at a low dose of radiation and a low dose of gene therapy product and thus is expected to be used in a cancer therapy method and a radiation-resistant cancer therapy method with no or little adverse effects.

公开(公告)号：EP4116421A1

公开(公告)日：2023-01-11

申请号：EP22767538.6

申请日：2022-03-10

申请人： RZNOMICS INC.

发明人： LEE, Seong-Wook ,  LEE, Kyung Hyun ,  HAN, Seung Ryul ,  KIM, Ji Hyun ,  KIM, Seongcheol

IPC分类号： C12N15/113 ,  C12N15/63

摘要： The self-circularization RNA construct of an example embodiment of the present disclosure can be expressed in a DNA vector and simultaneously circularized through a self-targeting & splicing reaction to form a circRNA, and the circRNA can consist only of a gene of interest. The gene of interest has the advantage of being able to rapidly express a peptide or protein, including an IRES region, an initiation codon, and a termination codon.

公开(公告)号：EP4071247A1

公开(公告)日：2022-10-12

申请号：EP21846099.6

申请日：2021-07-23

申请人： RZNOMICS INC.

发明人： LEE, Seong-Wook ,  KIM, Ji Hyun ,  HAN, Seung Ryul

IPC分类号： C12N15/113 ,  C12N15/86 ,  A61K31/713 ,  A61P27/02

摘要： The present invention relates to a trans-splicing ribozyme targeting a rhodopsin transcript and its use for the treatment and/or prophylaxis of retinitis pigmentosa.

公开(公告)号：EP3733213A1

公开(公告)日：2020-11-04

申请号：EP20158701.1

申请日：2020-02-21

申请人： Rznomics Inc.

发明人： Lee, Seong-Wook ,  Lee, Chang Ho ,  Han, Seung Ryul ,  Kim, Ji Hyun ,  Cho, Eun Yi ,  Jeong, Jin Sook ,  Ju, Mi Ha

IPC分类号： A61K48/00 ,  C12N15/113

摘要： The present invention relates to a cancer-specific trans-splicing ribozyme and a use thereof. Since a trans-splicing ribozyme according to the present invention does not act on normal tissue, but is specifically expressed in cancer tissue, it is very safe and has excellent expression efficiency at the post-transcription level, and thus can be effectively used in treatment of cancer. Specifically, as a recombinant vector of the present invention has a CMV promoter and SD/SA and WPRE sequences, the recombinant vector has high ribozyme expression efficiency, and as the recombinant vector of the present invention has miR-122T, it can regulate activity related to miR-122, and it is very safe to utilize. Therefore, the recombinant vector of the present invention can be effectively used in treatment of all types of liver cancer, except some types of liver cancer caused by HCV in which miR-122 expression is highly shown in the cancer tissue in comparison to normal tissue, and the recombinant vector also can be effectively used in treatment of other carcinomas in which miR-122 is not substantially expressed.

公开(公告)号：EP3202909A4

公开(公告)日：2018-05-23

申请号：EP15847264

申请日：2015-07-23

申请人： RZNOMICS INC

发明人： LEE SEONG WOOK ,  KIM JU HYUN ,  JEONG JIN SOOK ,  HAN SANG YOUNG

IPC分类号： C12N15/85 ,  A61K31/713 ,  A61K38/43 ,  A61P35/00 ,  C12N9/22

CPC分类号： A61K31/713 ,  A61K38/00 ,  A61K38/43 ,  C12N15/1135 ,  C12N15/85 ,  C12N15/86 ,  C12N2310/113 ,  C12N2310/124 ,  C12N2330/51 ,  C12N2710/10343 ,  C12N2830/008 ,  C12N2830/42 ,  C12N2830/48

摘要： The present invention relates to a recombination vector, a transformation cell into which the recombinant vector is introduced, a ribozyme expressed from the recombination vector, a prophylactic or therapeutic composition for liver cancer comprising the recombination vector and the ribozyme, and a therapeutic method for liver cancer using the composition, said recombination vector comprising: a tissue-specific promoter; and a ribozyme-target gene expression cassette comprising a trans-splicing ribozyme targeting a cancer-specific gene and a target gene connected to the 3' exon of the ribozyme, wherein a splicing donor/splicing acceptor sequence (SD/SA sequence) is connected to the 5' end of the ribozyme-target gene expression cassette, woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) is connected to the 3' end of the ribozyme-target gene expression cassette, and a nucleic acid sequence recognizing a micro RNA-122a (microRNA-122a, miR-122a) is further connected to the 3' end of the WPRE.